A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2014
At a glance
- Drugs CHS 131; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors InteKrin Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2010 Six-month data will be presented at the American Diabetes Association annual meeting in June 2010, according to an InteKrin Therapeutics media release.
- 08 Oct 2009 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History